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Diagnostic endoscopic retrograde cholangiopancreatography (D-ERCP) is commonly performed for the evaluation of biliary
complications after orthotopic liver transplantation (OLT). This practice is contrary to the national trend of reserving endo-
scopic retrograde cholangiopancreatography (ERCP) for therapeutic purposes. Our aim was to evaluate the clinical yield
and complications of D-ERCP in OLT recipients. In this retrospective study, 165 OLT recipients who underwent ERCP
between January 2006 and December 2010 at the University of Michigan were divided into 2 groups: (1) a therapeutic en-
doscopic retrograde cholangiopancreatography (T-ERCP) group (if they met prespecified criteria that suggested a high likeli-
hood of endoscopic intervention) and (2) a D-ERCP group (if there was clinical suspicion of biliary disease but they did not
meet any criteria). The 2 groups were compared with respect to the proportion of subjects undergoing high-yield ERCP,
which was defined as a procedure resulting in a clinically important intervention that modified the disease course. 66.3% of
the D-ERCP procedures were classified as high-yield, whereas 90.1% of the T-ERCP procedures were (P < 0.001). Serious
complications were infrequent in both groups. A survey of practitioners caring for OLT recipients suggested that the rate of
high-yield D-ERCP seen in this study is congruent with what is considered acceptable in clinical practice. In conclusion,
although T-ERCP is more likely to reveal a pathological process requiring an intervention, D-ERCP appears to be an accept-
able clinical strategy for OLT recipients because of the high likelihood of a high-yield study and the low rate of serious com-
plications. Liver Transpl 18:1479-1484, 2012. VC 2012 AASLD.
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Endoscopic retrograde cholangiopancreatography
(ERCP), initially developed as a diagnostic test, has
evolved into a mature therapeutic platform for various
pancreaticobiliary interventions.1 The concurrent
maturation of endoscopic ultrasound and magnetic
resonance cholangiopancreatography (MRCP) now
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allows highly accurate pancreaticobiliary imaging
without the significant risks of ERCP.2-4
Consequently, the utilization of diagnostic endo-
scopic retrograde cholangiopancreatography (D-ERCP)
has steadily declined in favor of less invasive but diag-
nostically comparable endoscopic ultrasound and
MRCP, reserving ERCP for patients with a high pre-
test probability of therapeutic intervention.1,5 This
trend is consistent with recent clinical practice guide-
lines on the role of endoscopy in the evaluation of
choledocholithiasis and with the National Institutes of
Health consensus statement on ERCP for diagnosis
and therapy: both favor less invasive tests over ERCP
in the diagnosis of biliary disease.6,7
Despite the widespread practice of reserving ERCP
for patients with a high likelihood of therapeutic inter-
vention, the evaluation of biliary complications in
recipients of orthotopic liver transplantation (OLT)
remains an area in which D-ERCP is commonly per-
formed.8,9 This incongruence with contemporary
ERCP practice may be due to multiple factors, includ-
ing the high prevalence of biliary disease in OLT
recipients,10 the absence of data supporting the wide-
spread use of MRCP in this patient population,11 and
the low reported rate of post–endoscopic retrograde
cholangiopancreatography pancreatitis (PEP) in trans-
plant patients.12
Indeed, the evaluation of biliary complications after
liver transplantation may be one of the few scenarios
in which D-ERCP remains appropriate, although data
to support this approach are lacking. We hypothesized
that OLT recipients may undergo D-ERCP excessively,
and this places them at unnecessary risk that could
be avoided by the more routine use of noninvasive
evaluations. As such, we sought to determine the clin-
ical yield and complications of D-ERCP in OLT recipi-
ents in an effort to better define the risk-benefit ratio
of this strategy.
PATIENTS AND METHODS
To test our hypothesis, we performed a single-center,
retrospective cohort analysis comparing the clinical
outcomes and complications for OLT recipients
undergoing ERCP for diagnostic purposes (D-ERCP)
and OLT recipients undergoing ERCP for therapeutic
purposes [therapeutic endoscopic retrograde cholan-
giopancreatography (T-ERCP)]. A survey of the per-
ceptions of liver transplant professionals on this topic
was also performed.
Patients
After approval of the research protocol by the institu-
tional review board of the University of Michigan, all
adult patients undergoing OLT at the University of
Michigan from January 1, 2006 to December 31,
2010 were identified from an internal administrative
database. The transplant patients’ electronic medical
records were manually reviewed to determine whether
or not each patient had undergone ERCP after trans-
plantation. OLT recipients who had undergone ERCP
at least once served as the study population.
Data Extraction
After eligible subjects were identified, the electronic
medical record of each patient was reviewed, and clin-
ical, laboratory, and radiographic data were
abstracted to standardized forms in a duplicate and
independent fashion by 2 investigators (B.J.E. and
A.T.D.). Discrepancies were discussed by the investi-
gators and resolved by consensus. The following data
were extracted when they were available: age; indica-
tion for OLT; time between OLT and index ERCP; pre-
ERCP liver function test results (aspartate amino-
transferase, alanine aminotransferase, alkaline phos-
phatase, and total bilirubin), pre-ERCP liver biopsy
results; pre-ERCP imaging; pre-ERCP peritoneal fluid
bilirubin levels; indication for ERCP (based on pro-
gress notes or procedure reports); ERCP findings; liver
function test results 2 to 3 weeks after ERCP; and
complications developing within 3 weeks of ERCP,
including pancreatitis, bleeding, perforation, infection,
and morbidity related to anesthesia (all were defined
with consensus criteria).13,14 Only data pertaining to
a subject’s first posttransplant ERCP procedure were
extracted.
Study Groups
Eligible patients were divided into 2 groups: the D-
ERCP group and the T-ERCP group. The T-ERCP con-
sisted of patients undergoing ERCP for one of the fol-
lowing indications: (1) evidence of a bile duct stone,
cast, or stricture on percutaneous transhepatic chol-
angiography, MRCP, computed axial tomography (CT),
or transabdominal ultrasound; (2) abnormal liver
tests and biliary ductal dilation on percutaneous
transhepatic cholangiography, magnetic resonance
imaging, CT, or transabdominal ultrasound; (3) evi-
dence of a bile leak on a radionucleotide scan and/or
peritoneal fluid aspirate showing a fluid-to-serum bili-
rubin ratio  2; or (4) a liver biopsy sample indicating
a large bile duct obstruction (as evidenced by some
combination of centrilobular canalicular cholestasis,
an intense periportal cholestatic ductular reaction,
neutrophil invasion of ducts, biliary plugging, and di-
lation/proliferation of biliary ductules). In clinical
practice, any of these scenarios would justify ERCP
immediately with the intent to provide therapy. All
other patients not meeting these criteria but clinically
suspected to have biliary disease were assigned to the
D-ERCP group.
Study Outcomes
The primary endpoint of the study was whether or not
a study patient underwent high-yield cholangiography
(HYC), which was characterized as a procedure pro-
viding the opportunity for a clinically important
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intervention that modified the disease course. Specifi-
cally, HYC was defined as any of the following: (1)
ERCP in which a stone, cast, or bile leak was defini-
tively identified; (2) ERCP in which stent placement
across a stricture resulted in a >50% reduction of
the 2 most elevated liver function tests within 2
weeks of the intervention; and (3) ERCP in which a
biliary sphincterotomy for ampullary stenosis
resulted in a >50% reduction of the 2 most elevated
liver function tests within 2 weeks of the interven-
tion. There were several scenarios suggestive of HYC
but not specifically meeting the aforementioned crite-
ria. In those cases, the ERCP findings and clinical
outcomes were presented to a panel of 3 arbiters (an
ERCP endoscopist, a transplant surgeon, and a
transplant hepatologist) who were blinded to the
patient group, and whether or not the ERCP proce-
dure was high-yield was adjudicated by majority
decision.
The secondary endpoints of the study were the fre-
quency and type of post-ERCP complications. As men-
tioned previously, the complications of interest were
pancreatitis, bleeding, perforation, infection, and mor-
bidity related to anesthesia; all were defined with
standard criteria.13,14
Statistical Analysis and Implications of the
Results
We assumed that 95% of the T-ERCP subjects would
undergo HYC; this accounted for the small percentage
of false-positive noninvasive imaging tests that would
lead to occasional low-yield procedures in this group.
We estimated that with at least 118 subjects (59 per
study arm), the study would have 80% power to
detect a 20% difference in HYC between the T-ERCP
group (95% HYC) and the D-ERCP group (75% HYC)
on the basis of Fisher’s exact test with a 2-sided sig-
nificance level of 0.05. A difference of less than 20%
between the groups would lead to the conclusion that
the diagnostic yields of D-ERCP and T-ERCP are
essentially equivalent in OLT recipients, and this
would cause us to reject our hypothesis and accept
that a strategy of initial D-ERCP is justifiable for this
patient population.
For the analysis of the primary endpoint, the differ-
ence in the proportions of patients undergoing HYC in
the D-ERCP group and the T-ERCP group was ana-
lyzed with Fisher’s exact test, with a final 2-sided P
value < 0.05 indicating statistical significance. The
secondary endpoint was also analyzed with Fisher’s
exact test, although the sample size was not large
enough to determine equivalence in complication
rates between the 2 groups.
Practitioner Survey
Because there were no prior studies exploring the role
of D-ERCP in transplant practice and the acceptable
rate of negative ERCP in a patient population is a
subjective value judgment, we conducted a survey
exploring provider perceptions of the appropriateness
of D-ERCP in OLT recipients. An electronic survey
was designed to assess the current practices and per-
ceptions of transplant surgeons, transplant hepatolo-
gists, and endoscopists who perform ERCP in trans-
plant recipients with respect to the utilization of
various diagnostic tests, including D-ERCP, in OLT
recipients. Two questions within the survey directly
addressed the main focus of this study:
1. In transplant recipients with a duct-to-duct
anastomosis, what do you believe is a reasonable
rate of negative ERCP results (ie, ERCP by which
no relevant pathological process is identified or
treated)? In other words, out of every 10 ERCP
procedures, it is acceptable to have X or fewer
that are negative/normal.
2. In nontransplant recipients, what do you believe
is a reasonable rate of negative ERCP results (ie,
ERCP by which no pathological process is identi-
fied or treated)? In other words, out of every 10
ERCP procedures, it is acceptable to have X or
fewer that are negative/normal.
A list of survey participants and corresponding e-
mail addresses was generated from member directo-
ries of the American Society for Gastrointestinal En-
doscopy (ASGE; ie, endoscopists) and the American
Society of Transplantation (AST; ie, surgeons and
hepatologists). Survey recipients were asked to partic-
ipate only if they were involved in the care of liver
transplant recipients as a transplant surgeon, a
transplant hepatologist, or an endoscopist performing
ERCP in transplant recipients. Consent to participate
in this study was inferred from the completion of this
voluntary and anonymous survey, which was
approved by the institutional review board of the Uni-
versity of Michigan.
Surveys were distributed electronically in Septem-
ber 2011, with a reminder e-mail sent 2 weeks later.
All responses received before October 13, 2011 were
included in the analysis. The statistical difference
between the responses to the 2 questions was ana-
lyzed with the Student t test.
RESULTS
Patients
During the 5-year study period, 406 liver transplants
were performed in adults at the University of Michi-
gan Medical Center. One hundred sixty-seven of these
transplants in 165 patients were complicated by
actual or suspected biliary complications prompting
ERCP (2 subjects underwent 2 transplants during the
study period, and each subject required ERCP at least
once).
Patients ranged in age from 28 to 70 years (mean ¼
52.5 years). Sixty-five (39%) were women, and 100
(61%) were men. The most common etiologies of end-
stage liver disease were hepatitis C virus (44%),
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alcohol (19%), cryptogenic cirrhosis (7.2%), and non-
alcoholic steatohepatitis (6.6%; Table 1).
D-ERCP Versus T-ERCP
According to our predefined criteria, 86 ERCP proce-
dures (51.5%) were performed for diagnostic pur-
poses, and the remaining 81 were performed for ther-
apeutic reasons. The characteristics of the patients in
the D-ERCP and T-ERCP groups, including the
results of pre-ERCP liver function tests, the numbers
of patients with suspected biliary obstructions or bile
leaks, and the number of patients with confirmed bili-
ary pathologies, are also listed in Table 1.
ERCP Indications
Eighty-four of the 86 D-ERCP patients were suspected
of having biliary disease on the basis of abnormal
liver function tests, but there was no associated radi-
ographic evidence of biliary pathology. Sixty-three of
these D-ERCP patients had undergone at least 1 neg-
ative radiographic test (ultrasound, CT, hepatobiliary
iminodiacetic acid scan, or magnetic resonance imag-
ing). The remaining 23 had abnormal liver tests but
underwent no structural evaluation before ERCP. Two
patients in the D-ERCP group did not have abnormal
liver function tests; both of these patients underwent
cholangiography for an evaluation of unexplained
fever and leukocytosis in the context of a small
amount of intra-abdominal fluid visualized by
transabdominal ultrasound. All but 2 patients in
the T-ERCP group met at least 1 of the eligibility
criteria listed in the Patients and Methods section; 2
patients underwent ERCP for the retrieval of proxi-
mally migrated bile duct stents placed during
transplantation.
ERCP Yield
Overall, 130 of the 167 ERCP procedures (78%) per-
formed in the study population were classified as
high-yield by the investigators, and the remaining 37
procedures (22%) were not. In the D-ERCP group,
66.3% of the procedures (57/86) were considered
HYC, whereas 90.1% (73/81) were in the T-ERCP
group. This difference was statistically significant (P <
0.001; Fig. 1).
Complications
Twenty-two ERCP procedures (13.2%) resulted in
complications of varying severity. Nine of these
occurred in the D-ERCP group, and 13 occurred in
the T-ERCP group (P ¼ 0.36; Fig. 1).
Four complications were severe in nature. One
patient experienced an iatrogenic bile duct perforation
TABLE 1. Characteristics of the Study Population
D-ERCP (n ¼ 86) T-ERCP (n ¼ 81) P Value
Mean age (years) 51.9 53.3
Females [n (%)] 33 (38.4) 32 (39.5)
Males [n (%)] 53 (61.6) 49 (60.5)
Mean time between OLT and ERCP (months) 2.97 2.93
Etiology [n (%)]
Hepatitis C virus 37 (43) 37 (46)
Alcohol 22 (26) 13 (16) 0.09
Cryptogenic cirrhosis 7 (8) 6 (7)
Nonalcoholic steatohepatitis 5 (6) 6 (7)
Mean alanine aminotransferase before ERCP (IU/L) 218 141 0.01
Mean alkaline phosphatase before ERCP (IU/L) 295 239 0.07
Mean total bilirubin before ERCP (MG/DL) 4.96 2.70 <0.01
Suspected biliary obstruction before ERCP [n (%)] 61 (71) 29 (36) <0.01
Documented biliary obstruction during ERCP [n (%)] 40 (47) 38 (47) 0.96
Suspected bile leak before ERCP [n (%)] 38 (44) 48 (59) 0.05
Documented bile leak during ERCP [n (%)] 24 (28) 45 (56) <0.01
NOTE: Several patients in both groups were suspected of having concurrent biliary obstructions and bile leaks. Seventeen
percent of high-yield ERCP procedures confirmed concurrent biliary obstructions and bile leaks.
Figure 1. Percentages of high-yield ERCP procedures and
overall and severe complications in the D-ERCP and T-ERCP
groups.
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that required surgical intervention and a prolonged
stay in the intensive care unit, and it eventually led to
death. Another patient experienced a retroperitoneal
perforation during cannulation and rapid occlusion of
an indwelling endobiliary stent; this combination
resulted in bacteremia and hypotension. A third
patient developed an occlusion of his endobiliary stent
that was complicated by ascending cholangitis and
sepsis syndrome. The last patient developed massive,
hemodynamically significant postsphincterotomy
hemorrhaging that required angiographic intervention
and a 10-day intensive care unit stay. All 4 of these
severe complications occurred in the T-ERCP group.
Three patients (1.8%) developed PEP: 2 cases were
mild, and 1 was moderate. None of these cases of
pancreatitis resulted in any long-term adverse seque-
lae. Two of these complications occurred after T-
ERCP, and 1 occurred after D-ERCP.
The remaining 15 complications were all related to
endobiliary stent dysfunction (obstruction or migra-
tion) resulting in abdominal pain and/or abnormal
liver function tests. All these complications were man-
aged by repeat ERCP, and in several cases, a brief
hospitalization was required.
Practitioner Survey Results
In all, 5768 surveys were distributed electronically
(1537 to AST members and 4231 to ASGE members).
The majority of the surveys distributed to ASGE mem-
bers were expected to reach physicians not involved
in the care of liver transplant recipients. Similarly,
some of the surveys distributed to AST members were
expected to reach physicians caring for recipients of
nonliver solid organs.
If we assume that there are 120 liver transplant
centers in the United States and we estimate that
each transplant center has approximately 10 physi-
cians who care for liver transplant patients (3 sur-
geons, 3 hepatologists, and 4 endoscopists), approxi-
mately 1200 eligible physicians could have received
the survey. One hundred thirty-seven (11%) were
completed and analyzed. Seventy-four of the respond-
ents were 75 endoscopists, 37 were hematologists,
and 25 were transplant surgeons.
The mean number of negative ERCP procedures per
10 procedures in liver transplant recipients consid-
ered acceptable by our survey respondents was 3.3
(95% CI ¼ 3.04-3.62). In contrast, the mean number
of negative ERCP procedures per 10 procedures in
nonliver transplant patients considered acceptable
was 2.5 (95% CI ¼ 2.2-2.83). This difference was stat-
istically significant (P < 0.01). In other words, physi-
cians judged it appropriate for ERCP in OLT recipi-
ents to result in a clinically important intervention at
a rate of 67%.
DISCUSSION
In this study, ERCP performed with the primary
intent of delivering therapy (T-ERCP) was significantly
more likely than D-ERCP to reveal a pathological pro-
cess requiring endoscopic intervention. Nevertheless,
2 of every 3 D-ERCP procedures were high-yield
examinations and revealed a clinically relevant patho-
logical finding; this led us to question our hypothesis
that D-ERCP is overused in OLT recipients. The over-
all rate of serious ERCP-related complications was
low in both groups, as was the risk of PEP.
Although there was a statistically significant differ-
ence between the 2 groups, the high rate of high-yield
D-ERCP and the low risk of complications in this
patient population suggest that D-ERCP in liver trans-
plant recipients may in fact be a justifiable clinical
strategy. Moreover, the delay in care necessary to con-
duct a full pre-ERCP diagnostic evaluation, the cost
savings associated with not mandating MRCP to prove
the necessity of ERCP in all intermediate-risk cases,
and the importance of excluding biliary complications
in real time are additional justifications for D-ERCP in
OLT recipients.
Indeed, the 66% rate of high-yield D-ERCP in this
study is congruent with the acceptable rate of nega-
tive ERCP reported by our survey respondents, who in
aggregate indicated that a mean of 3.3 or fewer nega-
tive/normal ERCP procedures per every 10 proce-
dures in OLT recipients is justifiable.
Ultimately, the acceptable rate of negative ERCP in
transplant recipients is a value judgment made by
individual practitioners and based on the perceived
pretest probability of biliary complications, the per-
ceived absence of an adequate and timely alternative
diagnostic method, and the expected complication
rate of the procedure. Although this study cannot pro-
duce definitive recommendations, it is the first to pro-
vide objective data about the diagnostic yield and
complications of D-ERCP that can inform the deci-
sion-making process influencing this value judgment.
Four patients in our study developed serious com-
plications related to ERCP. Although all 4 of these
patients were in the T-ERCP group, there is no reason
to believe that complications of this magnitude cannot
occur in patients undergoing D-ERCP. Therefore, even
though the results of this analysis may support a
strategy of D-ERCP in select OLT recipients, the risk-
benefit ratio of subjecting individual patients to ERCP
should be thoughtfully considered in every case. The
decision to proceed with ERCP in transplant recipi-
ents should never be taken lightly because of the
small but real risk of a life-threatening complication.
Moreover, additional studies are necessary to assess
the utility of MRCP in low-urgency, moderate-proba-
bility cases of suspected biliary obstruction.
Another finding of this study that warrants further
discussion is the very low rate of PEP in liver trans-
plant recipients. Notably, we included only patients’
first posttransplant ERCP procedures in this study,
and the large majority of these subjects had not
undergone ERCP before transplantation. The first
ERCP procedure is believed to confer the highest risk
of pancreatitis because most subsequent procedures
will be performed through an existing biliary
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sphincterotomy, which protects against PEP by sepa-
rating the biliary and pancreatic orifices. Therefore,
the 1.8% rate of PEP would likely have been much
lower if all post-OLT ERCP procedures had been con-
sidered in this analysis. The overall rate of complica-
tions and the low risk of pancreatitis are consistent
with previously reported data for transplant
patients,12,15,16 and they underscore the importance
of further studies aimed at determining the factors
that protect transplant recipients from PEP. Decipher-
ing these factors may have implications for under-
standing the pathophysiology of PEP and preventing
pancreatitis in nontransplant patients undergoing
ERCP.
The results of this study should be interpreted in
the context of several important limitations. First, this
was an observational study in which confounding var-
iables may have led to important differences between
the groups that could have affected the high-yield
ERCP rate. For example, it is reasonable to assume
that some of the D-ERCP patients could have actually
been included in the T-ERCP group had additional
testing been performed (not all D-ERCP patients had
undergone transabdominal ultrasound, radionucleo-
tide scans, and MRCP). These possible misclassifica-
tions may have inflated the HYC rate in the diagnostic
group. Second, our study used a relatively small sam-
ple from a single medical center, and thus the results
may not be universally generalizable. Third, the retro-
spective nature of the study makes it likely that not
all complications were captured, and our reported
PEP rate may be falsely low. Finally, the survey
response rate was only 11%, and our response sample
may not have accurately reflected the perceptions of
the liver transplant community at large. Nevertheless,
this study is the first to comprehensively evaluate the
common practice of D-ERCP in liver transplant
recipients.
In summary, D-ERCP appears to be a reasonable
clinical approach in liver transplant recipients with
suspected biliary complications because of the high
likelihood of a high-yield study and the low rate of
complications. To optimize the risk-benefit ratio of
ERCP in this patient population, further studies are
needed for identifying combinations of easily accessi-
ble clinical and laboratory factors that predict the
presence of biliary pathologies. Moreover, additional
investigations focusing on understanding the low risk
of PEP in OLT recipients are warranted.
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